Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

NCT05894889 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Stage IIIB(N2) Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab 200 mg IV infusion

Sponsor

Peking University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]